Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Michael Scott Gordon, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R41MD012261 (VOCCI, FRANK J.) Sep 24, 2019 - Aug 31, 2020
    NIH/NIMHD
    The Daily Progress System - A Recovery Support Tool to Reduce Health Disparities in Outpatient Substance Use Treatment
    Role: Principal Investigator
  2. UG1DA050077 (GORDON, MICHAEL SCOTT) Jul 15, 2019 - Apr 30, 2024
    NIH
    A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail
    Role: Principal Investigator
  3. R01DA043476 (GORDON, MICHAEL SCOTT) Jul 15, 2018 - Apr 30, 2023
    NIH
    Buprenorphine for probationers and parolees: Bridging the gap into treatment
    Role: Principal Investigator
  4. R01DA040636 (GORDON, MICHAEL SCOTT) Aug 15, 2016 - Apr 30, 2022
    NIH
    Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment
    Role: Principal Investigator
  5. R41MD009540 (GORDON, MICHAEL SCOTT) Aug 1, 2015 - Jul 31, 2017
    NIH
    Avatar Assisted Therapy for Probationers and Parolees with Substance Use Disorders
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Crable EL, Blue TR, McKenzie M, Rich JD, Gordon MS. Effect of Case Management on HIV Outcomes for Community Corrections Population: Results of an 18-Month Randomized Controlled Trial. J Acquir Immune Defic Syndr. 2021 May 01; 87(1):755-762. PMID: 33492021.
    Citations:    Fields:    
  2. Apolo AB, Ellerton JA, Infante JR, Agrawal M, Gordon MS, Aljumaily R, Gourdin T, Dirix L, Lee KW, Taylor MH, Schöffski P, Wang D, Ravaud A, Manitz J, Pennock G, Ruisi M, Gulley JL, Patel MR. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. J Immunother Cancer. 2020 10; 8(2). PMID: 33037118.
    Citations: 3     Fields:    
  3. Voss MH, Gordon MS, Mita M, Rini B, Makker V, Macarulla T, Smith DC, Cervantes A, Puzanov I, Pili R, Wang D, Jalal S, Pant S, Patel MR, Neuwirth RL, Enke A, Shou Y, Sedarati F, Faller DV, Burris HA. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. Br J Cancer. 2020 11; 123(11):1590-1598. PMID: 32913286.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  4. In GK, Poorman K, Saul M, O'Day S, Farma JM, Olszanski AJ, Gordon MS, Thomas JS, Eisenberg B, Flaherty L, Weise A, Daveluy S, Gibney G, Atkins MB, Vanderwalde A. Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases. Oncotarget. 2020 Aug 18; 11(33):3118-3128. PMID: 32913556.
    Citations: 1     Fields:    
  5. Chiang AC, Sequist LVD, Gilbert J, Conkling P, Thompson D, Marcoux JP, Gettinger S, Kowanetz M, Molinero L, O'Hear C, Fassò M, Lam S, Gordon MS. Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer. Clin Lung Cancer. 2020 09; 21(5):455-463.e4. PMID: 32586767.
    Citations:    Fields:    
  6. Murphy SM, Jeng PJ, Poole SA, Jalali A, Vocci FJ, Gordon MS, Woody GE, Polsky D. Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials. Addict Sci Clin Pract. 2020 04 22; 15(1):15. PMID: 32321570.
    Citations:    Fields:    
  7. Middleton G, Yang Y, Campbell CD, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, De Vos F, Van Cutsem E, Millholland JM, Brase JC, Rangwala F, Gasal E, Corcoran RB. BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. Clin Cancer Res. 2020 06 01; 26(11):2466-2476. PMID: 32047001.
    Citations: 3     Fields:    
  8. Mita MM, LoRusso PM, Papadopoulos KP, Gordon MS, Mita AC, Ferraldeschi R, Keer H, Oganesian A, Su XY, Jueliger S, Tolcher AW. A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma. Clin Cancer Res. 2020 06 15; 26(12):2819-2826. PMID: 31900279.
    Citations: 4     Fields:    
  9. Sullivan RJ, Hollebecque A, Flaherty KT, Shapiro GI, Rodon Ahnert J, Millward MJ, Zhang W, Gao L, Sykes A, Willard MD, Yu D, Schade AE, Crowe K, Flynn DL, Kaufman MD, Henry JR, Peng SB, Benhadji KA, Conti I, Gordon MS, Tiu RV, Hong DS. A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. Mol Cancer Ther. 2020 02; 19(2):460-467. PMID: 31645440.
    Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
  10. O'Donnell PH, Arkenau HT, Sridhar SS, Ong M, Drakaki A, Spira AI, Zhang J, Gordon MS, Degboe AN, Gupta AK, Mukhopadhyay P, Huang W, Abdullah SE, Angra N, Roskos LK, Guo X, Friedlander T. Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108. Cancer. 2020 01 15; 126(2):432-443. PMID: 31581306.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  11. Jameson GS, Borazanci E, Babiker HM, Poplin E, Niewiarowska AA, Gordon MS, Barrett MT, Rosenthal A, Stoll-D'Astice A, Crowley J, Shemanski L, Korn RL, Ansaldo K, Lebron L, Ramanathan RK, Von Hoff DD. Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial. JAMA Oncol. 2019 Oct 03. PMID: 31580386.
    Citations: 12     Fields:    
  12. Gerber DE, Infante JR, Gordon MS, Goldberg SB, Martín M, Felip E, Martinez Garcia M, Schiller JH, Spigel DR, Cordova J, Westcott V, Wang Y, Shames DS, Choi Y, Kahn R, Dere RC, Samineni D, Xu J, Lin K, Wood K, Royer-Joo S, Lemahieu V, Schuth E, Vaze A, Maslyar D, Humke EW, Burris HA. Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. Clin Cancer Res. 2020 01 15; 26(2):364-372. PMID: 31540980.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  13. Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, Cervantes A, Ochoa de Olza M, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott D, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey K, Mahrus S, Morley R, Pirzkall A, Davis SL. Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. Clin Cancer Res. 2019 06 01; 25(11):3220-3228. PMID: 30770348.
    Citations: 27     Fields:    Translation:HumansCTClinical Trials
  14. Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, O'Hear C, Fassò M, Molinero L, Schmid P. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol. 2019 01 01; 5(1):74-82. PMID: 30242306.
    Citations: 95     Fields:    Translation:HumansCTClinical Trials
  15. Hellerstedt BA, Vogelzang NJ, Kluger HM, Yasenchak CA, Aftab DT, Ramies DA, Gordon MS, Lara P. Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma. Clin Lung Cancer. 2019 03; 20(2):74-81.e1. PMID: 30528315.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  16. Hussong AM, Gottfredson NC, Bauer DJ, Curran PJ, Haroon M, Chandler R, Kahana SY, Delaney JAC, Altice FL, Beckwith CG, Feaster DJ, Flynn PM, Gordon MS, Knight K, Kuo I, Ouellet LJ, Quan VM, Seal DW, Springer SA. Approaches for creating comparable measures of alcohol use symptoms: Harmonization with eight studies of criminal justice populations. Drug Alcohol Depend. 2019 01 01; 194:59-68. PMID: 30412898.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  17. Babiker HM, Byron SA, Hendricks WPD, Elmquist WF, Gampa G, Vondrak J, Aldrich J, Cuyugan L, Adkins J, De Luca V, Tibes R, Borad MJ, Marceau K, Myers TJ, Paradiso LJ, Liang WS, Korn RL, Cridebring D, Von Hoff DD, Carpten JD, Craig DW, Trent JM, Gordon MS. E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases. Invest New Drugs. 2019 08; 37(4):636-645. PMID: 30264293.
    Citations: 5     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  18. Horn L, Gettinger SN, Gordon MS, Herbst RS, Gandhi L, Felip E, Sequist LV, Spigel DR, Antonia SJ, Balmanoukian A, Cassier PA, Liu B, Kowanetz M, O'Hear C, Fassò M, Grossman W, Sandler A, Soria JC. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Eur J Cancer. 2018 09; 101:201-209. PMID: 30077125.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  19. Grisham RN, Moore KN, Gordon MS, Harb W, Cody G, Halpenny DF, Makker V, Aghajanian CA. Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders. Clin Cancer Res. 2018 11 15; 24(22):5525-5533. PMID: 29844129.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  20. Shah MA, Starodub A, Sharma S, Berlin J, Patel M, Wainberg ZA, Chaves J, Gordon M, Windsor K, Brachmann CB, Huang X, Vosganian G, Maltzman JD, Smith V, Silverman JA, Lenz HJ, Bendell JC. Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. Clin Cancer Res. 2018 08 15; 24(16):3829-3837. PMID: 29691300.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  21. Goss GD, Vokes EE, Gordon MS, Gandhi L, Papadopoulos KP, Rasco DW, Fischer JS, Chu KL, Ames WW, Mittapalli RK, Lee HJ, Zeng J, Roberts-Rapp LA, Loberg LI, Ansell PJ, Reilly EB, Ocampo CJ, Holen KD, Tolcher AW. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor. Cancer. 2018 05 15; 124(10):2174-2183. PMID: 29533458.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  22. Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini BI. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. 2018 04; 19(4):451-460. PMID: 29530667.
    Citations: 52     Fields:    Translation:HumansCTClinical Trials
  23. Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Cancer Discov. 2018 04; 8(4):428-443. PMID: 29431699.
    Citations: 105     Fields:    Translation:HumansCellsCTClinical Trials
  24. Nebot N, Arkenau HT, Infante JR, Chandler JC, Weickhardt A, Lickliter JD, Sarantopoulos J, Gordon MS, Mak G, St-Pierre A, Tang L, Mookerjee B, Carson SW, Hayes S, Grossmann KF. Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours. Br J Clin Pharmacol. 2018 04; 84(4):764-775. PMID: 29243287.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  25. Loeliger KB, Biggs ML, Young R, Seal DW, Beckwith CG, Kuo I, Gordon MS, Altice FL, Ouellet LJ, Cunningham WE, Young JD, Springer SA. Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A "Seek, Test, Treat, and Retain" Harmonization Consortium. AIDS Behav. 2017 Oct; 21(10):2945-2957. PMID: 28188460.
    Citations: 5     Fields:    Translation:Humans
  26. Diamond JR, Goff B, Forster MD, Bendell JC, Britten CD, Gordon MS, Gabra H, Waterhouse DM, Poole M, Ross Camidge D, Hamilton E, Moore KM. Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers. Invest New Drugs. 2017 10; 35(5):627-633. PMID: 28283779.
    Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
  27. Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer. 2017 Feb 14; 116(4):432-440. PMID: 28103611.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  28. Nance RM, Delaney JA, Golin CE, Wechsberg WM, Cunningham C, Altice F, Christopoulos K, Knight K, Quan V, Gordon MS, Springer S, Young J, Crane PK, Mayer KH, Mugavero MJ, Del Rio C, Kronmal RA, Crane HM. Co-calibration of two self-reported measures of adherence to antiretroviral therapy. AIDS Care. 2017 04; 29(4):464-468. PMID: 27910703.
    Citations: 2     Fields:    Translation:Humans
  29. Gordon MS, Herbst RS, Horn L, Soria JC, Gandhi L, Felip E, Sequist L, Spigel DR, Antonia SJ, Balmanoukian A, Cassier P, Liu B, Kowanetz M, O'Hear C, Fassò M, Sandler A, Gettinger SN. PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11(11S):S309-S310. PMID: 27969529.
    Citations: 2     Fields:    
  30. Gordon MS, Gordon MB. Occult Langerhans Cell Histiocytosis Presenting with Papillary Thyroid Carcinoma, a Thickened Pituitary Stalk and Diabetes Insipidus. Case Rep Endocrinol. 2016; 2016:5191903. PMID: 27656301.
    Citations: 3     
  31. Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016 09 10; 34(26):3119-25. PMID: 27269937.
    Citations: 234     Fields:    Translation:HumansCTClinical Trials
  32. Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O'Brien CP. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. N Engl J Med. 2016 Mar 31; 374(13):1232-42. PMID: 27028913.
    Citations: 79     Fields:    Translation:HumansPHPublic Health
  33. Infante JR, Mendelson DS, Burris HA, Bendell JC, Tolcher AW, Gordon MS, Gillenwater HH, Arastu-Kapur S, Wong HL, Papadopoulos KP. A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors. Invest New Drugs. 2016 Apr; 34(2):216-24. PMID: 26924128.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  34. McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, Powderly JD, Infante JR, Fassò M, Wang YV, Zou W, Hegde PS, Fine GD, Powles T. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. J Clin Oncol. 2016 Mar 10; 34(8):833-42. PMID: 26755520.
    Citations: 162     Fields:    Translation:HumansCellsCTClinical Trials
  35. Young P, Gordon MS. Mental health screening in immigration detention: A fresh look at Australian government data. Australas Psychiatry. 2016 Feb; 24(1):19-22. PMID: 26755798.
    Citations: 7     Fields:    Translation:HumansPHPublic Health
  36. Mitchell SG, Willet J, Monico LB, James A, Rudes DS, Viglione J, Schwartz RP, Gordon MS, Friedmann PD. Community correctional agents' views of medication-assisted treatment: Examining their influence on treatment referrals and community supervision practices. Subst Abus. 2016; 37(1):127-33. PMID: 26860334.
    Citations: 9     Fields:    Translation:Humans
  37. Vocci FJ, Schwartz RP, Wilson ME, Gordon MS, Kinlock TW, Fitzgerald TT, O'Grady KE, Jaffe JH. Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners. Drug Alcohol Depend. 2015 Nov 01; 156:133-138. PMID: 26409751.
    Citations: 4     Fields:    Translation:Humans
  38. Gordon MS, Kinlock TW, Vocci FJ, Fitzgerald TT, Memisoglu A, Silverman B. A Phase 4, Pilot, Open-Label Study of VIVITROL® (Extended-Release Naltrexone XR-NTX) for Prisoners. J Subst Abuse Treat. 2015 Dec; 59:52-8. PMID: 26299956.
    Citations: 13     Fields:    Translation:Humans
  39. Green J, Melvin GA, Newman L, Jones M, Taffe J, Gordon M. Day program for young people with anorexia nervosa. Australas Psychiatry. 2015 Jun; 23(3):249-53. PMID: 25948510.
    Citations: 2     Fields:    Translation:Humans
  40. Eppler S, Gordon MS, Redfern CH, Trudeau C, Xu N, Han K, Lum BL. Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive metastatic or locally advanced inoperable solid tumors. Anticancer Drugs. 2015 Apr; 26(4):448-55. PMID: 25643049.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  41. Solomon PM, Bryce BA, Kuroda MA, Keech R, Shetty S, Shaw TM, Copel M, Hung LW, Schrott AG, Armstrong C, Gordon MS, Reuter KB, Theis TN, Haensch W, Rossnagel SM, Miyazoe H, Elmegreen BG, Liu XH, Trolier-McKinstry S, Martyna GJ, Newns DM. Pathway to the piezoelectronic transduction logic device. . 2015 Apr 08; 15(4):2391-5. PMID: 25793915.
    Citations: 3     
  42. Sarma A, Shyn PB, Vivian MA, Ng JM, Tuncali K, Lorch JH, Zaheer SN, Gordon MS, Silverman SG. Single-Session CT-Guided Percutaneous Microwave Ablation of Bilateral Adrenal Gland Hyperplasia Due to Ectopic ACTH Syndrome. Cardiovasc Intervent Radiol. 2015 Oct; 38(5):1335-8. PMID: 25762486.
    Citations: 1     Fields:    Translation:Humans
  43. Lee JD, Friedmann PD, Boney TY, Hoskinson RA, McDonald R, Gordon M, Fishman M, Chen DT, Bonnie RJ, Kinlock TW, Nunes EV, Cornish JW, O'Brien CP. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial. Contemp Clin Trials. 2015 Mar; 41:110-7. PMID: 25602580.
    Citations: 8     Fields:    Translation:HumansPHPublic Health
  44. Gordon MS, Springett GM, Su YB, Ould-Kaci M, Wind S, Zhao Y, LoRusso PM. A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors. Future Oncol. 2015; 11(10):1479-91. PMID: 25963426.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  45. Suttle AB, Grossmann KF, Ouellet D, Richards-Peterson LE, Aktan G, Gordon MS, LoRusso PM, Infante JR, Sharma S, Kendra K, Patel M, Pant S, Arkenau HT, Middleton MR, Blackman SC, Botbyl J, Carson SW. Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib. J Clin Pharmacol. 2015 Apr; 55(4):392-400. PMID: 25449654.
    Citations: 9     Fields:    Translation:Humans
  46. Dickson MA, Gordon MS, Edelman G, Bendell JC, Kudchadkar RR, LoRusso PM, Johnston SH, Clary DO, Schwartz GK. Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2015 Apr; 33(2):349-56. PMID: 25476894.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  47. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27; 515(7528):563-7. PMID: 25428504.
    Citations: 1535     Fields:    Translation:HumansCellsCTClinical Trials
  48. Cox DS, Allred A, Zhou Y, Infante JR, Gordon MS, Bendell J, Jones S, Burris H, Orford K. Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors. Clin Pharmacol Drug Dev. 2015 07; 4(4):287-94. PMID: 27136909.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  49. Xu N, Redfern CH, Gordon M, Eppler S, Lum BL, Trudeau C. Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1251-60. PMID: 25344761.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  50. Kwong N, Marqusee E, Gordon MS, Larsen PR, Garber JR, Kim MI, Alexander EK. Long-term, treatment-free survival in select patients with distant metastatic papillary thyroid cancer. Endocr Connect. 2014 Dec; 3(4):207-14. PMID: 25316293.
    Citations: 8     
  51. Gordon MS, Robert F, Matei D, Mendelson DS, Goldman JW, Chiorean EG, Strother RM, Seon BK, Figg WD, Peer CJ, Alvarez D, Adams BJ, Theuer CP, Rosen LS. An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2014 Dec 01; 20(23):5918-26. PMID: 25261556.
    Citations: 25     Fields:    Translation:HumansCTClinical Trials
  52. Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor AO, Vogelzang NJ, Gordon MS, de Bono JS, Haas NB, Logothetis CJ, Elfiky A, Scheffold C, Laird AD, Schimmoller F, Basch EM, Scher HI. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol. 2014 Oct 20; 32(30):3391-9. PMID: 25225437.
    Citations: 46     Fields:    Translation:HumansCellsCTClinical Trials
  53. Gordon MS, Melvin GA. Do antidepressants make children and adolescents suicidal? J Paediatr Child Health. 2014 Nov; 50(11):847-54. PMID: 24941902.
    Citations: 1     Fields:    Translation:Humans
  54. Carvajal RD, Wong MK, Thompson JA, Gordon MS, Lewis KD, Pavlick AC, Wolchok JD, Rojas PB, Schwartz JD, Bedikian AY. A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma. Eur J Cancer. 2014 Aug; 50(12):2099-107. PMID: 24930625.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  55. Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O'Grady KE, Vocci FJ. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend. 2014 Sep 01; 142:33-40. PMID: 24962326.
    Citations: 30     Fields:    Translation:Humans
  56. Gordon M, Melvin G. Risk assessment and initial management of suicidal adolescents. Aust Fam Physician. 2014 Jun; 43(6):367-72. PMID: 24897985.
    Citations: 6     Fields:    Translation:Humans
  57. Mita M, Gordon M, Rosen L, Kapoor N, Choy G, Redkar S, Taverna P, Oganesian A, Sahai A, Azab M, Bristow R, Tolcher AW. Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul; 74(1):195-204. PMID: 24849582.
    Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
  58. Gordon MS, Kinlock TW, Schwartz RP, Couvillion KA, Sudec LJ, O'Grady KE, Vocci FJ, Shabazz H. Buprenorphine Treatment for Probationers and Parolees. Subst Abus. 2015; 36(2):217-25. PMID: 24701967.
    Citations: 8     Fields:    Translation:Humans
  59. Gordon M, Melvin GA. Prescribing for depressed adolescents: office decision-making in the face of limited research evidence. J Paediatr Child Health. 2014 Jul; 50(7):498-503. PMID: 24617419.
    Citations: 1     Fields:    Translation:Humans
  60. Orsinger GV, Watson JM, Gordon M, Nymeyer AC, de Leon EE, Brownlee JW, Hatch KD, Chambers SK, Barton JK, Kostuk RK, Romanowski M. Simultaneous multiplane imaging of human ovarian cancer by volume holographic imaging. J Biomed Opt. 2014 Mar; 19(3):36020. PMID: 24676382.
    Citations: 3     Fields:    Translation:Humans
  61. Basch E, Autio KA, Smith MR, Bennett AV, Weitzman AL, Scheffold C, Sweeney C, Rathkopf DE, Smith DC, George DJ, Higano CS, Harzstark AL, Sartor AO, Gordon MS, Vogelzang NJ, de Bono JS, Haas NB, Corn PG, Schimmoller F, Scher HI. Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. Eur Urol. 2015 Feb; 67(2):310-8. PMID: 24631409.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  62. Rosen LS, Gordon MS, Robert F, Matei DE. Endoglin for targeted cancer treatment. Curr Oncol Rep. 2014 Feb; 16(2):365. PMID: 24445497.
    Citations: 32     Fields:    Translation:Humans
  63. Bhatia S, Curti B, Ernstoff MS, Gordon M, Heath EI, Miller WH, Puzanov I, Quinn DI, Flaig TW, VanVeldhuizen P, Byrnes-Blake K, Freeman JA, Bittner R, Hunder N, Souza S, Thompson JA. Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother Cancer. 2014; 2:2. PMID: 24829759.
    Citations: 15     Fields:    
  64. Donaldson AE, Gordon MS, Melvin GA, Barton DA, Fitzgerald PB. Addressing the needs of adolescents with treatment resistant depressive disorders: a systematic review of rTMS. Brain Stimul. 2014 Jan-Feb; 7(1):7-12. PMID: 24527502.
    Citations: 14     Fields:    Translation:Humans
  65. Hong DS, Gordon MS, Samlowski WE, Kurzrock R, Tannir N, Friedland D, Mendelson DS, Vogelzang NJ, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Appleman LJ. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2014 Jun; 12(3):167-177.e2. PMID: 24365125.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  66. Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, Agarwal N, Condon CH, Wilson D, Pearsall AE, Yang Y, McClure T, Attie KM, Sherman ML, Sharma S. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res. 2014 Jan 15; 20(2):480-9. PMID: 24173543.
    Citations: 25     Fields:    Translation:HumansCTClinical Trials
  67. Gordon MS, Melvin GA. Suicide risk assessment: where are we now? Med J Aust. 2013 Oct 21; 199(8):534. PMID: 24138374.
    Citations:    Fields:    Translation:Humans
  68. Wagner AJ, Chugh R, Rosen LS, Morgan JA, George S, Gordon M, Dunbar J, Normant E, Grayzel D, Demetri GD. A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clin Cancer Res. 2013 Nov 01; 19(21):6020-9. PMID: 24045182.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  69. Copel M, Kuroda MA, Gordon MS, Liu XH, Mahajan SS, Martyna GJ, Moumen N, Armstrong C, Rossnagel SM, Shaw TM, Solomon PM, Theis TN, Yurkas JJ, Zhu Y, Newns DM. Giant piezoresistive on/off ratios in rare-earth chalcogenide thin films enabling nanomechanical switching. . 2013 Oct 09; 13(10):4650-3. PMID: 24016226.
    Citations: 2     
  70. Gordon M, Melvin G. Selective serotonin re-uptake inhibitors--a review of the side effects in adolescents. Aust Fam Physician. 2013 Sep; 42(9):620-3. PMID: 24024221.
    Citations: 5     Fields:    Translation:Humans
  71. Papadopoulos KP, Burris HA, Gordon M, Lee P, Sausville EA, Rosen PJ, Patnaik A, Cutler RE, Wang Z, Lee S, Jones SF, Infante JR. A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Oct; 72(4):861-8. PMID: 23975329.
    Citations: 27     Fields:    Translation:HumansCTClinical Trials
  72. Melvin GA, Dudley AL, Gordon MS, Ford S, Taffe J, Tonge BJ. What happens to depressed adolescents? A follow-up study into early adulthood. J Affect Disord. 2013 Oct; 151(1):298-305. PMID: 23829999.
    Citations: 7     Fields:    Translation:Humans
  73. Gordon MS, Kinlock TW, McKenzie M, Wilson ME, Rich JD. Rapid HIV testing for individuals on probation/parole: outcomes of an intervention trial. AIDS Behav. 2013 Jul; 17(6):2022-30. PMID: 23536140.
    Citations: 20     Fields:    Translation:HumansPHPublic Health
  74. Gordon MS, Russo FA, MacDonald E. Spectral information for detection of acoustic time to arrival. Atten Percept Psychophys. 2013 May; 75(4):738-50. PMID: 23359354.
    Citations: 4     Fields:    Translation:Humans
  75. Ouellet D, Grossmann KF, Limentani G, Nebot N, Lan K, Knowles L, Gordon MS, Sharma S, Infante JR, Lorusso PM, Pande G, Krachey EC, Blackman SC, Carson SW. Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors. J Pharm Sci. 2013 Sep; 102(9):3100-9. PMID: 23608920.
    Citations: 8     Fields:    Translation:Humans
  76. Marshall J, Shapiro GI, Uttenreuther-Fischer M, Ould-Kaci M, Stopfer P, Gordon MS. Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer. Future Oncol. 2013 Feb; 9(2):271-81. PMID: 23414476.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  77. Connelly KL, Gordon MS. Is bedside teaching necessary or acceptable in paediatrics? Med J Aust. 2013 Jan 21; 198(1):25. PMID: 23330762.
    Citations:    Fields:    Translation:Humans
  78. Gordon MS, Mendelson DS, Gross M, Uttenreuther-Fischer M, Ould-Kaci M, Zhao Y, Stopfer P, Agus DB. A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs. 2013 Apr; 31(2):409-16. PMID: 23242861.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  79. Gordon MS, Ilaria R, de Alwis DP, Mendelson DS, McKane S, Wagner MM, Look KY, LoRusso PM. A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jan; 71(1):21-7. PMID: 23228983.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  80. Ribas A, Chesney JA, Gordon MS, Abernethy AP, Logan TF, Lawson DH, Chmielowksi B, Glaspy JA, Lewis K, Huang B, Wang E, Hsyu PH, Gomez-Navarro J, Gerhardt D, Marshall MA, Gonzalez R. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med. 2012 Nov 21; 10:236. PMID: 23171508.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  81. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013 Feb 01; 31(4):412-9. PMID: 23169517.
    Citations: 158     Fields:    Translation:HumansCTClinical Trials
  82. Gordon MS, Rosen LS, Mendelson D, Ramanathan RK, Goldman J, Liu L, Xu Y, Gerson SL, Anthony SP, Figg WD, Spencer S, Adams BJ, Theuer CP, Leigh BR, Weiss GJ. A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. Invest New Drugs. 2013 Jun; 31(3):714-23. PMID: 23054206.
    Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
  83. Wilson ME, Kinlock TW, Gordon MS, O'Grady KE, Schwartz RP. Postprison release HIV-risk behaviors in a randomized trial of methadone treatment for prisoners. Am J Addict. 2012 Sep-Oct; 21(5):476-87. PMID: 22882399.
    Citations: 7     Fields:    Translation:Humans
  84. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA, Messersmith WA. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug; 13(8):773-81. PMID: 22805291.
    Citations: 163     Fields:    Translation:HumansCTClinical Trials
  85. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug; 13(8):782-9. PMID: 22805292.
    Citations: 178     Fields:    Translation:HumansCTClinical Trials
  86. Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Gordon MS. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res. 2012 Sep 01; 18(17):4820-9. PMID: 22767667.
    Citations: 85     Fields:    Translation:HumansCTClinical Trials
  87. Matulonis UA, Sharma S, Ghamande S, Gordon MS, Del Prete SA, Ray-Coquard I, Kutarska E, Liu H, Fingert H, Zhou X, Danaee H, Schilder RJ. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol. 2012 Oct; 127(1):63-9. PMID: 22772063.
    Citations: 57     Fields:    Translation:HumansCTClinical Trials
  88. Zhang D, Vorndran S, Russo JM, Gordon M, Kostuk RK. Ultra light-trapping filters with broadband reflection holograms. Opt Express. 2012 Jun 18; 20(13):14260-71. PMID: 22714488.
    Citations: 1     Fields:    Translation:Cells
  89. Antshel KM, Faraone SV, Gordon M. Cognitive behavioral treatment outcomes in adolescent ADHD. J Atten Disord. 2014 Aug; 18(6):483-95. PMID: 22628140.
    Citations: 15     Fields:    Translation:Humans
  90. Infante JR, Rugg T, Gordon M, Rooney I, Rosen L, Zeh K, Liu R, Burris HA, Ramanathan RK. Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET. Invest New Drugs. 2013 Apr; 31(2):363-9. PMID: 22547164.
    Citations: 9     Fields:    Translation:HumansAnimalsCTClinical Trials
  91. Friedmann PD, Hoskinson R, Gordon M, Schwartz R, Kinlock T, Knight K, Flynn PM, Welsh WN, Stein LA, Sacks S, O'Connell DJ, Knudsen HK, Shafer MS, Hall E, Frisman LK. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Subst Abus. 2012; 33(1):9-18. PMID: 22263709.
    Citations: 53     Fields:    Translation:Humans
  92. Gordon MS, Tonge B, Melvin GA. The Self-Efficacy Questionnaire for Depressed Adolescents: a measure to predict the course of depression in depressed youth. Aust N Z J Psychiatry. 2012 Jan; 46(1):47-54. PMID: 22247093.
    Citations: 1     Fields:    Translation:Huma